HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
To evaluate the safety and efficacy of HAIC or Lenvatinib combined with Sintilimab as a neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma
Hepatocellular Carcinoma
DRUG: HAIC|DRUG: Sintilimab|DRUG: Lenvatinib
1-year DFS rate, To evaluate the 1-year disease free survival rate of neoadjuvant treatment with HAIC or Lenvatinib combined with Sintilimab for of high recurrence risk resectable stage IB solitary hepatocellular carcinoma, up to 1 years
Incidence of microvascular invasion, Defined as proportion of patients with microvascular invasion, Up to 3 years|Pathological complete response rate (pCR), Defined as proportion of patients who have a best response of pCR, up to 1 years|Objective response rate, Defined as proportion of patients who have a best response of CR or PR, Up to 1 years|2-year DFS rate, To evaluate the 2-year disease free survival rate of neoadjuvant treatment with HAIC or Lenvatinib combined with Sintilimab for of high recurrence risk resectable stage IB solitary hepatocellular carcinoma, Up to 3 years|2-year OS rate, To evaluate the 2-year overall survival rate of neoadjuvant treatment with HAIC or Lenvatinib combined with Sintilimab for of high recurrence risk resectable stage IB solitary hepatocellular carcinoma, Up to 3 years|Adverse Events (AEs), Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0 and complications of surgery, Up to 3 years
To evaluate the safety and efficacy of HAIC or Lenvatinib combined with Sintilimab as a neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma